

Amendment to the Claims

1-7 (Canceled)

8 (Original) A pharmaceutical composition comprising a protein useful for treating a lysosomal storage disorder other than Fabry disease that is selectively imported into macrophages when administered to a subject and a pharmaceutically acceptable carrier, wherein said protein is produced in an insect cell culture.

9 (Previously presented) The composition of claim 8 wherein said lysosomal storage disorder is Galactosialidosis.

10 (Previously presented) The composition of claim 8 wherein said protein is protective protein/cathepsin A (PPCA).

11 (Original) The composition of claim 8 wherein said insect cell culture comprises cells derived from the species selected from the group consisting of *Spodoptera frugiperda* and *Tricoplusia ni*.

12 (Original) The composition of claim 11 wherein said cells are *Spodoptera frugiperda* Sf9 cells.

13 (Original) The composition of claim 8 wherein said protein is produced in the cell culture using a baculovirus expression system.

14-20 (Canceled)

- 21 (New) The composition of claim 8 wherein said lysosomal storage disorder and associated protein useful for treating said lysosomal storage disorder are selected from the group consisting of Pompe Disease and acid α -1,4 glucosidase, Pompe Disease and acid α -1,6 glucosidase, GM1 gangliosidosis and β -galactosidase, Tay-Sachs disease and β -hexosaminidase A, GM2 gangliosialidosis: AB Variant and GM₂ Activator Protein, Sandhoff Disease and β -hexosaminidase A, Sandhoff Disease and β -hexosaminidase B, Gaucher Disease and glucocerebrosidase, Gaucher Disease and β -glucosidase, Krabbe Disease and galactosylcerebrosidase, Niemann-Pick Type A and acid sphingomyelinase, Niemann-Pick Type B and acid sphingomyelinase, Farber Disease and acid ceramidase, Wolman Disease and acid lipase, Cholesterol Ester Storage Disease and acid lipase, Hurler Syndrome and α -L-iduronidase, Scheie Syndrome and α -L-iduronidase, Hurler-Scheie and α -L-iduronidase, Hunter Syndrome and iduronate 2-sulfatase, Sanfilippo A and α -N-acetylglucosaminidase, Sanfilippo B and α -N-acetylglucosaminidase, Sanfilippo C and acetyl-CoA-glucosaminide acetyltransferase, Sanfilippo D and N-acetylglucosamine-6-sulfatase, Morquio A and N-acetylglucosamine-6-sulfate sulfatase, Morquio B and β -galactosidase, Maroteaux-Lamy and arylsulfatase B, Sly Syndrome and β -glucuronidase, Metachromatic Leukodystrophy and arylsulfatase A, Multiple Sulfatase Deficiency and arylsulfatase A, Multiple Sulfatase Deficiency and arylsulfatase B, Multiple Sulfatase Deficiency and arylsulfatase C, Sialidosis and α -Neuraminidase, I-Cell Disease and UDP GlcNAc:lysosomal-enzyme N-acetylglucosamine-1-phosphotransferase, Pseudo-Hurler Polydystrophy and UDP GlcNAc:lysosomal-enzyme N-acetylglucosamine-1-phosphotransferase, Mucopolipidosis IV and mucopolipin-1, α -Mannosidosis and α -mannosidase, β -Mannosidosis and β -mannosidase, Fucosidosis and α -L-fucosidase, Aspartylglucosaminuria and N-aspartyl- β -glucosaminidase, Galactosialidosis and protective protein/cathepsin A, Galactosialidosis and

neuraminidase, Galactosialidosis and β -galactosidase, Schindler Disease and α -N-acetyl-galactosaminidase, Cystinosis and cystine transport protein, Salla Disease and sialin, Infantile Sialic Acid Storage Disorder and sialin, Infantile Neuronal Ceroid Lipofuscinosis and palmitoyl-protein thioesterase, Prosaposin and Saposin A, Prosaposin and Saposin B, Prosaposin and Saposin C, and Prosaposin and Saposin D.

- 22 (New) The composition of claim 21 wherein said lysosomal storage disorder is Sialidosis and said protein useful for treating said lysosomal storage disorder is α -Neuraminidase.